Mark Mendel

Mark Mendel is an invention development manager at Intellectual Ventures. Prior to joining Intellectual Ventures, he served as a consultant and helped to nurture multiple biotech and medical device companies through their seed stage, including Proteon Therapeutics and ValveXchange, where he served as start-up CEO. Previously, Mark served as managing director of RiverVest Venture Partners, which he co-founded. While at RiverVest, he served as founding CEO and later Chairman of the Board of Auxeris Therapeutics. He also led investments in and served as a member of the board of CyDex, and as a board observer at Conforma Therapeutics (acquired by Biogen-Idec), CGI Pharmaceuticals, Inc. and Xcyte Therapeutics (acquired by Cyclacel Pharmaceuticals). Before RiverVest, Mark was a vice president with ARCH Venture Partners. Mark worked in medical research at the Scheie Eye Institute and at Massachusetts General Hospital, in product development at ALYX Medical, and in manufacturing at Polaroid. Mark earned his BS in mechanical engineering at Cornell University and received his MSE and PhD in bioengineering from the University of Pennsylvania.